Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

289
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
289
Dementia01:30

Dementia

591
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
591
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

686
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
686
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

253
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
253

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Safety Management Program on Critical Incidents During Patient Transport: Experience From Single Critical Care Transport System.

Journal of patient safety·2026
Same author

Predicting post-hepatectomy liver failure after hemi-hepatectomy using a combined model based on age, ALBI score, and the future liver remnant-to-spleen volume ratio.

Updates in surgery·2026
Same author

Racial and Ethnic Representation in Dementia Clinical Trials Registered on ClinicalTrials.gov in the United States, United Kingdom, and Canada.

International journal of geriatric psychiatry·2026
Same author

Alzheimer's Disease blood biomarkers measured through remote capillary sampling correlate with cognition in older adults.

Nature communications·2026
Same author

A conserved translational repression module buffers sugar-inducible root vascular proliferation.

Molecular plant·2026
Same author

Synuclein Disorder-Related Genetic Determinants of Mild Behavioural Impairment in a Pre-Clinical Community Cohort.

International journal of geriatric psychiatry·2026

Related Experiment Video

Updated: Feb 20, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

977

Alzheimer's drug-development pipeline: 2016.

Jeffrey Cummings1, Travis Morstorf2, Garam Lee1

  • 1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.

Alzheimer'S & Dementia (New York, N. Y.)
|October 26, 2017
PubMed
Summary

Alzheimer

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • Alzheimer's disease (AD) prevalence is increasing, necessitating novel therapeutic interventions.
  • The urgent need for effective Alzheimer's disease treatments drives research and development.

Purpose of the Study:

  • To analyze the landscape of Alzheimer's disease drug development trials.
  • To characterize agents and targets in various phases of clinical investigation for AD.

Main Methods:

  • Systematic review of clinical trials registered on clinicaltrials.gov (accessed January 4, 2016).
  • Categorization of trials by phase (I, II, III) and agent type (symptomatic, disease-modifying).

Main Results:

  • 36 Phase III trials involve 24 agents, with 17 disease-modifying treatments (DMTs) primarily targeting amyloid (76%).
Keywords:
Alzheimer's diseaseAmyloidBiomarkersCognitive enhancementDrug developmentPhase IPhase IIPhase IIITau

More Related Videos

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.9K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.7K

Related Experiment Videos

Last Updated: Feb 20, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

977
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.9K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.7K
  • 52 Phase II trials assess 45 agents, including 30 DMTs (26 small molecules, 4 immunotherapies).
  • 24 agents are in Phase I development for Alzheimer's disease.

    • Conclusions:

    • Amyloid-centric strategies dominate late-stage Alzheimer's drug development.
    • The limited number of agents in clinical trials indicates a need to expand the AD drug discovery pipeline.